-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, F8AWeVqgZzfZdSXfkZLe1JFkTiNsJduLStWyseTzp7+k4JMAYdVemBXgwjXjZH4u t/d6mE2WxDaLy5JtuL+lmA== 0000935836-01-500459.txt : 20020413 0000935836-01-500459.hdr.sgml : 20020413 ACCESSION NUMBER: 0000935836-01-500459 CONFORMED SUBMISSION TYPE: SC 13G PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20011214 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: KILKENNY CAPITAL MANAGEMENT LLC CENTRAL INDEX KEY: 0001133468 STANDARD INDUSTRIAL CLASSIFICATION: [] IRS NUMBER: 943219916 STATE OF INCORPORATION: DE FILING VALUES: FORM TYPE: SC 13G BUSINESS ADDRESS: STREET 1: ONE FINANCIAL PLACE, SUITE 1021 CITY: CHICAGO STATE: CA ZIP: 60605 BUSINESS PHONE: 3126633284 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: AXONYX INC CENTRAL INDEX KEY: 0001070698 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 860883978 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G SEC ACT: 1934 Act SEC FILE NUMBER: 005-60719 FILM NUMBER: 1813638 BUSINESS ADDRESS: STREET 1: 750 LEXINTTON AVE STREET 2: STE 1400 CITY: NEW YORK STATE: NY ZIP: 10022 BUSINESS PHONE: 2126884770 MAIL ADDRESS: STREET 1: 750 LEXINGTON AVE STREET 2: STE 1400 CITY: NEW YORK STATE: NY ZIP: 10022 SC 13G 1 axonyx13g.htm

SEC 1745

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0145

Expires: October 31, 2002

Estimated average burden

hours per response . . . .14.9

SCHEDULE 13G

Under the Securities Exchange Act of 1934
(Amendment No. ___________)

Axonyx, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

05461R101

(CUSIP Number)

December 4, 2001

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

[ ] Rule 13d-1(b)

[X] Rule 13d-1(c)

[ ] Rule 13d-1(d)

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

1. Names of Reporting Persons.
I.R.S. Identification Nos. of above persons (entities only).

KCM Biomedical, L.P.

2. Check the Appropriate Box if a Member of a Group (See Instructions)

(a) ______

(b) X

3. SEC Use Only

4. Citizenship or Place of Organization Delaware

Number of Shares Beneficially Owned by Each Reporting Person With	5. Sole Voting Power 0
	6. Shared Voting Power 1,059,000
	7. Sole Dispositive Power 0
	8. Shared Dispositive Power 1,059,000

9. Aggregate Amount Beneficially Owned by Each Reporting Person 1,059,000

10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See
Instructions) ______

11. Percent of Class Represented by Amount in Row (9) 6.0%

12. Type of Reporting Person (See Instructions)

1. Names of Reporting Persons.
I.R.S. Identification Nos. of above persons (entities only).

Kilkenny Capital Management, L.L.C.

2. Check the Appropriate Box if a Member of a Group (See Instructions)

(a) X

(b)

3. SEC Use Only

4. Citizenship or Place of Organization Delaware

Number of Shares Beneficially Owned by Each Reporting Person With	5. Sole Voting Power 0
	6. Shared Voting Power 1,455,000
	7. Sole Dispositive Power 0
	8. Shared Dispositive Power 1,455,000

9. Aggregate Amount Beneficially Owned by Each Reporting Person 1,455,000

10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See
Instructions) ______

11. Percent of Class Represented by Amount in Row (9) 8.2%

12. Type of Reporting Person (See Instructions)

IA, OO

1. Names of Reporting Persons.
I.R.S. Identification Nos. of above persons (entities only).

Michael P. Walsh

2. Check the Appropriate Box if a Member of a Group (See Instructions)

(a) X

(b)

3. SEC Use Only

4. Citizenship or Place of Organization U.S.A.

Number of Shares Beneficially Owned by Each Reporting Person With	5. Sole Voting Power 0
	6. Shared Voting Power 1,455,000
	7. Sole Dispositive Power 0
	8. Shared Dispositive Power 1,455,000

9. Aggregate Amount Beneficially Owned by Each Reporting Person 1,455,000

10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See
Instructions) ______

11. Percent of Class Represented by Amount in Row (9) 8.2%

12. Type of Reporting Person (See Instructions)

IN, HC

Item 1.

(a) Name of Issuer

Axonyx, Inc.

(b) Address of Issuer's Principal Executive Offices

825 Third Avenue, 40^th Floor
New York, New York 10022

Item 2.

(a) The names of the persons filing this statement are:

KCM Biomedical, L.P., a Delaware limited partnership ("KCM"), Kilkenny Capital Management, L.L.C., a Delware limited liability company ("LLC"), and Michael P. Walsh ("Walsh") (collectively, the "Filers").

KCM is filing this statement jointly with the other Filers, but not as a member of a group and expressly disclaims membership in any group.

(b) The principal business office of the Filers is located at:

One Financial Place, Suite 1021
Chicago, IL 60605

(d) This statement relates to shares of Common Stock of the Issuer (the "Stock").

(e) The CUSIP number of the Issuer is: 05461R101

Item 3. If this statement is filed pursuant to rule 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

(a) [ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

(b) [ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

(d) [ ] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

(e) [ ] An investment adviser in accordance with section 240.13d-1(b)(1)(ii)(E).

(f) [ ] An employee benefit plan or endowment fund in accordance with section 240.13d-1(b)(1)(ii)(F).

(g) [ ] A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G)

(h) [ ] A savings association as defined in section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).

(i) [ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3).

(j) [ ] Group, in accordance with section 240.13d-1(b)(1)(ii)(J).

Item 4. Ownership.

See Items 5-9 and 11 of the cover page for each Filer.

Item 5. Ownership of Five Percent or Less of a Class

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

LLC is an investment adviser whose clients have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Stock. Walsh is the Manager of LLC. LLC is the general partner of KCM, which is an investment limited partnership. No single client of LLC, other than KCM, holds more than five percent of the Stock.

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

Not applicable.

Item 8. Identification and Classification of Members of the Group.

See Item 2(a) of this Schedule.

Item 9. Notice of Dissolution of Group

Not applicable.

Item 10. Certification.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: December 14, 2001

KCM BIOMEDICAL, L.P.

By: Kilkenny Capital Management, L.L.C.,
General Partner

By: /s/ Michael P. Walsh

Michael P. Walsh
Manager

KILKENNY CAPITAL MANAGEMENT, L.L.C.

By: /s/ Michael P. Walsh

Michael P. Walsh

Manager

/s/ Michael P. Walsh

Michael P. Walsh

EXHIBIT A

AGREEMENT REGARDING JOINT FILING

OF STATEMENT ON SCHEDULE 13D OR 13G

The undersigned agree to file jointly with the Securities and Exchange Commission (the "SEC") any and all statements on Schedule 13D or Schedule 13G (and any amendments or supplements thereto) required under section 13(d) of the Securities Exchange Act of 1934, as amended, in connection with purchases by the undersigned of securities of Axonyx, Inc. and any other issuer, until such time as the undersigned file with the SEC a statement terminating this Agreement Regarding Joint Filing of Statement on Schedule 13D or 13G. For that purpose, the undersigned hereby constitute and appoint Kilkenny Capital Management, L.L.C., a Delaware limited liability company, as their true and lawful agent and attorney-in-fact, with full power and authority for and on behalf of the undersigned to prepare or cause to be prepared, sign, file with the SEC and furnish to any other person all certificates, instruments, agreements and documents necessary to comply with section 13(d) and section 16(a) of the Securities Exchange Act of 1934, as amended, in connection with said purchases, and to do and perform every act necessary and proper to be done incident to the exercise of the foregoing power, as fully as the undersigned might or could do if personally present, until such time as the undersigned file with the SEC a statement terminating this Agreement Regarding Joint Filing of Statement on Schedule 13D or 13G.

Dated: December 14, 2001

/s/ Michael P. Walsh

Michael P. Walsh

KCM BIOMEDICAL, L.P.

By: Kilkenny Capital Management, L.L.C.
General Partner

By: /s/ Michael P. Walsh

Michael P. Walsh

Manager

KILKENNY CAPITAL MANAGEMENT, L.L.C.

By: /s/ Michael P. Walsh

Michael P. Walsh

Manager

-----END PRIVACY-ENHANCED MESSAGE-----